157 related articles for article (PubMed ID: 33845380)
1. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
[TBL] [Abstract][Full Text] [Related]
2. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
Jiang F; Wang HJ; Bao QC; Wang L; Jin YH; Zhang Q; Jiang D; You QD; Xu XL
Bioorg Med Chem; 2016 Nov; 24(21):5431-5439. PubMed ID: 27647369
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
[TBL] [Abstract][Full Text] [Related]
4. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L
J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities.
Hu XL; He QW; Long H; Zhang LX; Wang R; Wang BL; Feng JH; Wang Q; Hou JQ; Zhang XQ; Ye WC; Wang H
J Nat Prod; 2021 Jul; 84(7):1954-1966. PubMed ID: 34170694
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antitumor evaluation of novel celastrol derivatives.
Xu M; Li N; Zhao Z; Shi Z; Sun J; Chen L
Eur J Med Chem; 2019 Jul; 174():265-276. PubMed ID: 31051401
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities.
Li N; Xu M; Bao N; Shi W; Li Q; Zhang X; Sun J; Chen L
Eur J Med Chem; 2018 Dec; 160():1-8. PubMed ID: 30316059
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
10. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
11. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
13. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
14. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
Zhao M; Ma J; Zhu HY; Zhang XH; Du ZY; Xu YJ; Yu XD
Mol Cancer; 2011 Aug; 10():104. PubMed ID: 21871133
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity
Li N; Xu M; Zhang L; Lei Z; Chen C; Zhang T; Chen L; Sun J
J Med Chem; 2022 Mar; 65(6):4578-4589. PubMed ID: 35238566
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.
Peng B; Xu L; Cao F; Wei T; Yang C; Uzan G; Zhang D
Mol Cancer; 2010 Apr; 9():79. PubMed ID: 20398364
[TBL] [Abstract][Full Text] [Related]
17. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
18. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.
Zhang Y; Zhang TJ; Li XY; Liang JW; Tu S; Xu HL; Xue WH; Qian XH; Zhang ZH; Zhang X; Meng FH
Eur J Med Chem; 2021 Jan; 210():112988. PubMed ID: 33189438
[TBL] [Abstract][Full Text] [Related]
19. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
